You just read:

Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial

News provided by

Amgen

Mar 23, 2011, 04:06 ET